Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Manuscript
  • Published:

CME, BCR/ABL Studies and Myeloproliferative Disorders

Imatinib mesylate suppresses cytokine synthesis by activated CD4 T cells of patients with chronic myelogenous leukemia

Leukemia volume 19, pages 1905–1911 (2005)Cite this article

Abstract

Although imatinib mesylate (IM) is highly effective at inducing complete cytogenetic remission in patients with chronic myelogenous leukemia (CML), it is known to suppress T-cell proliferation in vitro. As cytokines are required for T-cell proliferation, we investigated the effects of IM on cytokine synthesis by T cells of CML patients by assessing cytokine synthesis by activated CD4+ and CD8+ T cells in vitro. The activation of T cells in the whole blood of IM-treated patients (CML-IM) with Staphylococcus enterotoxin B resulted in significantly lower percentages of CD4+ T cells that synthesized interleukin 2 (P=0.017), interferon-gamma (P=0.010), and tumor necrosis factor-alpha (P=0.009) than did the activated T cells of control subjects. The addition of exogenous IM to the cultures of peripheral blood mononuclear cells of CML-IM patients reduced Th1 cytokine synthesis by the CD4+ T cells. Furthermore, IM therapy at clinical doses suppressed the tyrosine phosphorylation of ZAP70. These findings suggest that inhibition of ZAP70 signaling pathway and suppression of Th1 cytokine synthesis by CD4+ T cells required the presence of IM at the time of T-cell activation through the T-cell receptor.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  1. Sawyers CL . Chronic myeloid leukemia. N Engl J Med 1999; 340: 1330–1340.

    Article  CAS  Google Scholar 

  2. Goldman JM, Druker BJ . Chronic myeloid leukemia: current treatment options. Blood 2001; 98: 2039–2042.

    Article  CAS  Google Scholar 

  3. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001; 344: 1038–1042.

    Article  CAS  Google Scholar 

  4. Kantarjian HM, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gmbacorti-Passerini C et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002; 346: 645–652.

    Article  CAS  Google Scholar 

  5. Druker BJ . Imatinib as a paradigm of targeted therapies. Adv Cancer Res 2004; 90: 1–30.

    Google Scholar 

  6. Reuben JM, Lee B-N, Johnson H, Fritsche H, Kantarjian HM, Talpaz M . Restoration of Th1 cytokine synthesis by T cells of patients with chronic myelogenous leukemia in cytogenetic and hematologic remission with interferon-α. Clin Cancer Res 2000; 6: 1671–1677.

    CAS  PubMed  Google Scholar 

  7. Guarini A, Breccia M, Montefusco E, Petti MC, Zepparoni A, Vitale A et al. Phenotypic and functional characterization of the host immune compartment of chronic myeloid leukemia patients in complete hematological remission. Brit J Haematol 2001; 113: 136–142.

    Article  CAS  Google Scholar 

  8. Gao H, Lee B-N, Donato NJ, Talpaz M, Reuben JM . Imatinib (Gleevec, STI-571) suppresses cytokine production by normal T cells activated through T-cell receptor (TCR) signaling. J Allergy Clin Immunol 2005; 105: S221.

    Article  Google Scholar 

  9. Cwynarski K, Laylor R, Macchiarulo E, Goldman JM, Lombardi G, Melo JV et al. Imatinib inhibits the activation and proliferation of normal T lymphocytes in vitro. Leukemia 2004; 18: 1332–1339.

    Article  CAS  Google Scholar 

  10. Joss A, Akdis M, Faith A, Blaser K, Akdis CA . IL-10 directly acts on T cells by specifically altering the CD28 co-stimulatory pathway. Eur J Immunol 2000; 30: 1683–1690.

    Article  CAS  Google Scholar 

  11. Talpaz M, Kantarjian HM, McCredie KB, Trujillo JM, Keating MJ, Gutterman JU . Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha in chronic myelogenous leukemia. N Engl J Med 1986; 314: 1065–1069.

    Article  CAS  Google Scholar 

  12. Nylander S, Kalies I . Brefeldin A, but not monensin, completely blocks CD69 expression on mouse lymphocytes: efficacy of inhibitors of protein secretion in protocols for intracellular cytokine staining by flow cytometry. J Immunol Methods 1999; 224: 69–76.

    Article  CAS  Google Scholar 

  13. Lee B-N, Duvic M, Tang C-K, Buenos-Ramos C, Estrov Z, Reuben JM . Dysregulated synthesis of intracellular type 1 and type 2 cytokines by T cells of patients with cutaneous T-cell lymphoma. Clin Diagn Lab Immunol 1999; 6: 79–84.

    CAS  PubMed  PubMed Central  Google Scholar 

  14. Cohen MH, Williams G, Johnson JR, Duan J, Gobburu J, Rahman A et al. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin Cancer Res 2002; 8: 935–942.

    CAS  PubMed  Google Scholar 

  15. Truneh A, Albert F, Golstein P, Schmitt-Verhulst AM . Early steps of lymphocyte activation bypassed by synergy between calcium ionophores and phorbol ester. Nature 1985; 313: 318–320.

    Article  CAS  Google Scholar 

  16. Garcia C, Briggs C, Zhang L, Guan L, Gabriel JL, Rogers TJ . Molecular characterization of the putative T-cell receptor cavity of the superantigen staphylococcal enterotoxin B. Immunology 1998; 94: 160–166.

    Article  CAS  Google Scholar 

  17. Erickson S, Sangfelt O, Castro J, Heyman M, Einhorn S, Grander D . Interferon-alpha inhibits proliferation in human T lymphocytes by abrogation of interleukin-2 induced changes in cell cycle-regulatory proteins. Cell Growth Differ 1999; 10: 575–582.

    CAS  PubMed  Google Scholar 

  18. Julius M, Maroun C, Haughn L . Distinct roles for CD4 and CD8 coreceptors in antigen receptor signaling. Immunol Today 1993; 14: 177–183.

    Article  CAS  Google Scholar 

  19. Maroun CR, Julius M . Distinct roles for CD4 and CD8 as co-receptors in T cell receptor signalling. Eur J Immunol 1994; 24: 959–966.

    Article  CAS  Google Scholar 

  20. Ravichandran KS, Burakoff SJ . Evidence for differential intracellular signaling via CD4 and CD8 molecules. J Exp Med 1994; 179: 727–732.

    Article  CAS  Google Scholar 

  21. Dietz AB, Souan L, Knutson GJ, Bulur PA, Litzow MR, Vuk-Pavlovic S . Imatinib mesylate inhibits T-cell proliferation in vitro and delayed-type hypersensitivity in vivo. Blood 2004; 104: 1094–1099.

    Article  CAS  Google Scholar 

  22. Seggewiss R, Lore K, Greiner E, Magnusson MK, Price DA, Douek DC et al. Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner. Blood 2005; 105: 2473–2479.

    Article  CAS  Google Scholar 

  23. Mattiuzzi GN, Cortes JE, Talpaz M, Reuben J, Rios MB, Shan J et al. Development of Varicella–Zoster virus infection in patients with chronic myelogenous leukemia treated with imatinib mesylate. Clin Cancer Res 2003; 9: 976–980.

    CAS  Google Scholar 

  24. Yasukawa M, Yakushijin Y, Fujita S . Two distinct mechanisms of cytotoxicity mediated by herpes simplex virus-specific CD4+ human cytotoxic T cell clones. Clin Immunol Immunopathol 1996; 78: 70–76.

    Article  CAS  Google Scholar 

  25. Yasukawa M, Ohminami H, Yakushijin Y, Arai J, Hasegawa A, Ishida Y et al. Fas-independent cytotoxicity mediated by human CD4+ CTL directed against herpes simplex virus-infected cells. J Immunol 1999; 162: 6100–6106.

    CAS  PubMed  Google Scholar 

  26. Yotnda P, Huseyin F, Garcia-Pons F, Garcia Z, Gourru G, Vernant J-P et al. Cytotoxic T cell response against the chimeric p210 BCR-ABL protein in patients with chronic myelogenous leukemia. J Clin Invest 1998; 101: 2290–2296.

    Article  CAS  Google Scholar 

  27. Whittington R, Faulds D . Interleukin-2: a review of its pharmacologic properties and therapeutic use in patients with cancer. Drugs 1993; 46: 446–514.

    Article  Google Scholar 

Download references

Acknowledgements

We thank clinical and research nurses Shela M Broussard, Marilyn S Elopre, and Vilma T Lopez, whose perseverance made it possible to recruit the patients for this study. We also thank De-Yu Shen for technical assistance and Clement Nzegwu and Joanne Black for maintaining the patient database. This work was supported in part by grants from the National Aeronautics and Space Administration NAG 9-1454 01 (JMR) and the Leukemia-Lymphoma Society (NJD).

Author information

Authors and Affiliations

  1. Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

    H Gao, B-N Lee & J M Reuben

  2. Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

    M Talpaz & N J Donato

  3. Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

    J E Cortes & H M Kantarjian

Authors
  1. H Gao
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. B-N Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M Talpaz
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. N J Donato
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J E Cortes
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. H M Kantarjian
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. J M Reuben
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J M Reuben.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gao, H., Lee, BN., Talpaz, M. et al. Imatinib mesylate suppresses cytokine synthesis by activated CD4 T cells of patients with chronic myelogenous leukemia. Leukemia 19, 1905–1911 (2005). https://doi.org/10.1038/sj.leu.2403933

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2403933

Keywords

This article is cited by

Search

Advanced search

Quick links